Finerenone
Kerendia
- Dosage form
- Tablet
- Available strengths
- 10 mg, 20 mg, 40 mg
- Drug class
- Nonsteroidal mineralocorticoid receptor antagonist
- Common brand
- Kerendia
Clinical overview. Finerenone is a nonsteroidal mineralocorticoid receptor antagonist (brand name Kerendia) taken once daily to reduce the risk of kidney and cardiovascular complications in adults with chronic kidney disease and type 2 diabetes, and to reduce cardiovascular death and heart failure hospitalization in adults with heart failure with an ejection fraction of 40% or higher. Dosing depends on kidney function, and regular blood tests to monitor serum potassium and kidney function are required before starting and periodically during treatment because finerenone can cause hyperkalemia. It interacts significantly with CYP3A4 inhibitors and inducers and should not be combined with other potassium-raising medications without close monitoring.
Indication
Common therapeutic uses
- Finerenone is used as an add-on to standard therapy in adults with chronic kidney disease and type 2 diabetes to reduce the risk of end-stage kidney disease, sustained decline in kidney function, cardiovascular death, non-fatal heart attack, and hospitalization for heart failure.
- Finerenone is used as an add-on to standard therapy in adults with heart failure with left ventricular ejection fraction of 40% or higher, to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits.
Pregnancy
Risk assessment and monitoring considerations
- There are no human data on finerenone use during pregnancy, and it should not be used unless the benefit to the mother clearly outweighs the risk to the fetus.
- Animal studies showed the drug crosses the placenta and caused fetal developmental toxicity, including birth defects, at high exposures.
- Individuals of childbearing potential should use effective contraception while taking finerenone, and pregnancy should be ruled out before starting treatment.
Breastfeeding
Infant exposure considerations
- It is not known whether finerenone passes into human breast milk.
- Animal studies showed finerenone and its breakdown products are excreted in milk and caused adverse effects in nursing offspring.
- A decision should be made whether to discontinue breastfeeding or discontinue finerenone, weighing the benefit of breastfeeding against the individual's need for treatment.
Geriatrics
Dosing and tolerability considerations
- Clinical studies have not identified significant differences in effectiveness between patients over 65 and younger patients, but some older individuals may be more sensitive to the drug's effects.
- No dose adjustment is required based on age alone.
Pediatrics
Use in children and adolescents
- Finerenone is not authorized for pediatric use, as no data are available to Health Canada.
Dosage & Administration
Practical dosing and administration
- For chronic kidney disease with type 2 diabetes, the starting dose is 10 mg once daily if eGFR is 25 to under 60 mL/min/1.73m2, or 20 mg once daily if eGFR is 60 mL/min/1.73m2 or higher; the target maintenance dose is 20 mg once daily.
- For heart failure with ejection fraction 40% or higher, the starting dose is 10 mg once daily if eGFR is 25 to under 60 mL/min/1.73m2, or 20 mg once daily if eGFR is 60 mL/min/1.73m2 or higher; the target dose is up to 40 mg once daily depending on kidney function.
- Serum potassium and eGFR must be measured before starting treatment and re-measured 4 weeks after starting, restarting, or adjusting the dose to guide up-titration, dose maintenance, or temporary discontinuation.
- Treatment should not be started if serum potassium is above 5.0 mmol/L, and the dose must be withheld or reduced if potassium rises above threshold levels during treatment, with different thresholds for the CKD/T2D and heart failure indications.
- Initiation is not recommended in patients with eGFR below 25 mL/min/1.73m2, and treatment should be discontinued in end-stage kidney disease (eGFR below 15 mL/min/1.73m2).
- Avoid use in severe hepatic impairment (Child-Pugh C); in moderate hepatic impairment (Child-Pugh B), consider more frequent potassium monitoring.
- Tablets can be taken whole with water, with or without food, or crushed and mixed with water or soft food such as applesauce for patients unable to swallow whole tablets.
- If a dose is missed, it can be taken the same day as soon as remembered; otherwise skip it and resume the next day's dose as scheduled, without doubling up.
Overdose
Recognizing and responding to overdose
If overdose is suspected, seek emergency medical attention immediately or contact your regional Poison Control Centre without delay.
- No cases of adverse events from finerenone overdose in humans have been reported to date.
- The most likely effect of overdose is hyperkalemia (elevated blood potassium).
- Hyperkalemia occurring with overdose should be managed using standard treatment measures.
- Because finerenone is about 90% bound to plasma proteins, hemodialysis is not expected to remove it from the blood effectively.
Common side effects
Frequently reported tolerability concerns
- Elevated blood potassium (hyperkalemia) is common.
- High uric acid levels (hyperuricemia) are common.
- Low blood sodium (hyponatremia) may occur.
- Low blood pressure (hypotension) may occur.
- Itching (pruritus) may occur.
- Anemia may occur.
- A mild, reversible decrease in kidney filtration rate (eGFR) commonly occurs shortly after starting treatment.
Serious side effects
Findings that may require urgent assessment
Serious side effects require immediate discussion with the prescriber or emergency care.
- Hyperkalemia can, in rare cases, lead to serious or life-threatening irregular heart rhythms.
- Worsening kidney function, including acute kidney injury and renal failure requiring hospitalization, has occurred, more often in patients with heart failure.
- Symptomatic hypotension, including dizziness, fainting, or falls, can occur, especially during the early weeks of treatment.
- Hypersensitivity (drug allergy) reactions have been reported.
- Seek urgent medical attention for muscle weakness, irregular heartbeat, severe dizziness, or fainting while taking finerenone.
Use with caution
Situations requiring closer assessment
- Use with caution and monitor serum potassium more frequently in patients with a low starting eGFR, higher baseline potassium, or a history of hyperkalemia.
- Use with caution in patients also taking other medications that raise potassium, including potassium supplements, potassium-sparing diuretics, or other mineralocorticoid receptor antagonists.
- Use with caution and consider additional potassium monitoring in patients taking weak or moderate CYP3A4 inhibitors.
- Use with caution and consider additional monitoring in patients taking trimethoprim or trimethoprim-sulfamethoxazole, since temporary discontinuation of finerenone may be needed.
- Use with caution in patients with moderate hepatic impairment (Child-Pugh B), with additional potassium monitoring.
- Use with caution in patients who develop clinically significant worsening kidney function during treatment; consider delaying dose increases or interrupting treatment.
- Avoid concomitant grapefruit or grapefruit juice, since it is expected to raise finerenone blood levels.
- Patients with rare hereditary galactose intolerance or glucose-galactose malabsorption should not take finerenone, due to its lactose content.
Contraindications
Situations where therapy may be inappropriate
- Contraindicated in patients with known hypersensitivity to finerenone or to any ingredient in the formulation, including any non-medicinal ingredient or component of the container.
- Contraindicated in patients taking strong CYP3A4 inhibitors, such as itraconazole, ketoconazole, ritonavir, clarithromycin, or nelfinavir.
- Contraindicated in patients with Addison's disease.
Drug interactions
Clinically relevant combinations
- Strong CYP3A4 inhibitors, such as itraconazole and clarithromycin, markedly increase finerenone exposure and are contraindicated.
- Moderate CYP3A4 inhibitors, such as erythromycin and verapamil, significantly increase finerenone exposure and require additional potassium monitoring.
- Weak CYP3A4 inhibitors, such as fluvoxamine, modestly increase finerenone exposure and warrant potassium monitoring.
- Strong CYP3A4 inducers, such as rifampicin, carbamazepine, phenytoin, and St. John's wort, markedly decrease finerenone exposure and reduce its effectiveness; concomitant use should be avoided.
- Moderate CYP3A4 inducers, such as efavirenz and phenobarbital, decrease finerenone exposure and should also be avoided.
- Potassium-sparing diuretics, such as amiloride and triamterene, increase the risk of hyperkalemia and should be avoided with finerenone.
- Other mineralocorticoid receptor antagonists, such as eplerenone and spironolactone, increase the risk of hyperkalemia and should be avoided with finerenone.
- Potassium supplements increase the risk of hyperkalemia and require caution and monitoring.
- Trimethoprim, alone or combined with sulfamethoxazole, increases the risk of hyperkalemia and may require temporary discontinuation of finerenone.
- Finerenone modestly increases exposure to sensitive CYP3A4 substrates with a narrow therapeutic window, such as cyclosporine and tacrolimus, at the 40 mg dose.
- Finerenone modestly increases exposure to sensitive CYP2C8 substrates, such as repaglinide, at the 40 mg dose.
- Finerenone does not meaningfully affect the levels of digoxin or rosuvastatin.
Food interactions
Meal-related administration
- Finerenone can be taken with or without food.
- Avoid grapefruit and grapefruit juice, which are expected to raise finerenone blood levels.
Time of administration
Practical scheduling
- Take finerenone once daily at approximately the same time each day, with a glass of water.
Storage
Product handling
- Store bottles and blisters at room temperature, 15°C to 30°C.
- Keep out of the reach and sight of children.
Patient take-away
Key counselling points for a quick closing summary
- Kerendia (finerenone) is taken once daily to help protect the kidneys and heart in people with chronic kidney disease and type 2 diabetes, or in certain types of heart failure.
- Regular blood tests to check potassium levels and kidney function are required before starting and periodically during treatment.
- Avoid grapefruit and grapefruit juice, and tell your healthcare professional about all other medications you take, since several can raise finerenone levels or increase potassium.
- Seek medical attention for muscle weakness, irregular heartbeat, or severe dizziness, which can signal high potassium levels.
References
Source material and product information
For professional reference. Confirm patient-specific decisions against the current approved product monograph and applicable clinical guidance.